Three Independent Investment Opportunities
A clinical-stage antiviral dermatology program with immediate commercial revenue, a structured ophthalmic immunomodulation asset, and a disruptive portable medical device for the global dialysis market.
Request Confidential Investment DeckErpeCream®
Antiviral Dermatology · Phase IIb Ongoing
The Opportunity
ErpeCream® is a first-in-class topical immunomodulator for recurrent genital HSV-2. Already registered as a dermocosmetic in EU and UK, it generates revenue today. Phase IIb (head-to-head vs acyclovir) will create a hard value inflection point.
Target Market
Investment Options
- Ticket minimum: €1.000.000
- Total Investment: €5.5M
- Timeline: 7–9 months
- 80 patients, 10 sites, head-to-head vs acyclovir
- Objective: demonstrate superiority vs acyclovir, licensing trigger
- Ticket minimum: €1.000.000
- Total Investment: €13.99M (budget PPD)
- Timeline: 24–26 months
- 420 patients, 39 sites, 7 countries
- Objective: approved drug (Rx) with global license
Exit
- Licensing post-Phase IIb (trigger at readout)
- Strategic acquisition post-Phase III
- IPO as secondary exit
Investment Structure
For each investment, a dedicated SPV vehicle (simplified limited liability company) will be established to hold the stake in the program.
- • Asset separation between investors
- • Governance proportional to investment
- • Transparency on milestones and returns
- • Individual exit for each investor
ACRO-EYE™
Ophthalmic Immunomodulation · Phase III Ready
The Opportunity
ACRO-EYE™ is an alcohol-free Tacrolimus-based ophthalmic solution for keratoconjunctivitis sicca (autoimmune dry eye). Galenic use already established. No direct market equivalent. Market signals: 2-3 big pharma in preliminary acquisition discussions post-registration.
Target Market
Investment Required
- Ticket minimum: €1.000.000
- Total Program Investment: €9.5M (Phase III)
- Timeline: 10–12 months to registration-ready data
- Structure: Phase III co-development with shared governance
Exit
- Post-registration acquisition by big pharma (interest already expressed by 2-3 companies)
- Regional or global licensing
Investment Structure
A dedicated SPV vehicle will be established for investment in ACRO-EYE™, with proportional governance and full transparency on milestones and returns.
Easy-Dialysis™
MedTech Nephrology · Portable Hemodialysis
The Opportunity
Easy-Dialysis™ is the first portable hemodialysis system in suitcase format. No dominant portable solution exists in a €90B+ market. Prototype completed, CE Marking pathway defined. Discussions with industrial partners ongoing.
Target Market
Investment Required
- Ticket minimum: €500.000
- Total Investment: €3–4M (clinical validation + CE Marking)
- Timeline: 10–12 months
- Structure: industrial co-development or equity investment
Exit
- Acquisition by major player (Baxter acquired NxStage for $1.3B in 2019)
- Industrial licensing
- Joint venture for manufacturing
Investment Structure
A dedicated SPV vehicle will be established for investment in Easy-Dialysis™, with proportional governance and full transparency on milestones and returns.
Request Confidential Investment Deck
For qualified investors